James Gutmann
Family Medicine · Evansville, INNPI 1790851897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 49 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$125
- Novo Nordisk$67
- Abbott$66
- Takeda Pharmaceuticals U.S.A., Inc.$63
- Lilly USA, LLC$57
- GSK$52
- plus $263 from 11 others
Across 89 payments — averaging $3483.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$148K
- Pfizer$127K
- AstraZeneca$19K
- Novo Nordisk AS$14K
- Novartis$2K
What the payments were for
- Food & beverage$693100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $125 |
| Novo Nordisk | 5 | $67 |
| Abbott | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Lilly USA, LLC | 4 | $57 |
| GSK | 4 | $52 |
| Boehringer Ingelheim | 4 | $48 |
| Amgen(2 entities) | 3 | $47 |
| Pfizer | 5 | $31 |
| Genentech USA, Inc. | 2 | $25 |
| Merck | 2 | $24 |
| Amarin Pharma, Inc. | 2 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| AbbVie | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$693 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Haloperidol | 25 | $470 |
| Topiramate | 13 | $186 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $186 |
| Atorvastatin Calcium | 15 | $183 |
| ClopidogrelClopidogrel Bisulfate | 13 | $140 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Evansville
- Anthony InzerelloEvansville$308K
- Carol GoodmanEvansville$123K
- David SchultzEvansville$22K
- J Christopher SartoreEvansville$19K
- David BrougherEvansville$18K
- Hubert ReyesEvansville$18K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.